Phase 2 PREDICT-ILD imaging study commences in interstitial lung disease - PharmaTimes
Serac Healthcare and University of Exeter start Phase II study on 99mTc-maraciclatide, a SPECT imaging agent for ILD prognostication. PREDICT-ILD aims to assess CT effectiveness in ILD progression detection, with a sub-study evaluating 99mTc-maraciclatide. Recruitment ongoing at three NHS sites, led by Professors Scotton and Dixon, funded by Wellcome Trust. Sub-study to compare 99mTc-maraciclatide uptake between IPF, non-IPF fibrosing-ILD, and healthy controls, aiming to predict disease progression.
Related Clinical Trials
Highlighted Terms
Related News
Researchers at the University of Exeter and Serac Healthcare Ltd are developing a new molecular imaging marker, <sup>99m</sup>Tc-maraciclatide, to detect interstitial lung disease progression. The PREDICT-ILD study aims to evaluate its potential for early diagnosis, which could improve patient outcomes and aid in the development of new therapies.
A new molecular imaging marker, <sup>99m</sup>Tc-maraciclatide, could help identify interstitial lung disease progression sooner. The PREDICT-ILD study aims to evaluate this marker for disease prognostication, assessing differences between IPF, non-IPF fibrosing-ILD patients, and healthy controls. The study, led by the University of Exeter in collaboration with Serac Healthcare, hopes to improve patient outcomes and develop new therapies.
Serac Healthcare and the University of Exeter announce the first patient scan using <sup><span class="xn-money">99m</span></sup>Tc-maraciclatide in the PREDICT-ILD Phase II study, aiming to evaluate its efficacy as an imaging marker for ILD prognostication. The study, led by Professors Chris Scotton and Giles Dixon, is funded by the Wellcome Trust and involves 69 participants, with 15 in the sub-study. The primary endpoint is to compare <sup><span class="xn-money">99m</span></sup>Tc-maraciclatide uptake between IPF, non-IPF fibrosing-ILD, and healthy controls.
Serac Healthcare and University of Exeter start Phase II study on 99mTc-maraciclatide, a SPECT imaging agent for ILD prognostication. PREDICT-ILD aims to assess CT effectiveness in ILD progression detection, with a sub-study evaluating 99mTc-maraciclatide. Recruitment ongoing at three NHS sites, led by Professors Scotton and Dixon, funded by Wellcome Trust. Sub-study to compare 99mTc-maraciclatide uptake between IPF, non-IPF fibrosing-ILD, and healthy controls, aiming to predict disease progression.
Researchers at the University of Exeter and Serac Healthcare Ltd are evaluating <sup>99m</sup>Tc-maraciclatide, a novel imaging agent, in the PREDICT-ILD study to predict interstitial lung disease progression. The study aims to improve early detection and treatment, supported by the Wellcome Trust and NIHR Exeter Biomedical Research Centre.